Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy DOI Creative Commons
Shuang Ma, Guangyu Zhao,

S.J. Sui

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Cancer immunotherapy, which leverages the immune system to target neoplastic cells, has undergone significant transformation in recent. However, immunotherapy may have negative effects on skeletal muscle function, causing wasting and functional decline cancer patients. In this study, we review mechanisms by influences muscle, focusing immune-related myositis, inflammation, metabolic alterations within tumor microenvironment (TME). The key methodologies, including biomechanical assessment techniques such as electrical impedance myography ultrasound imaging, are discussed provide valuable insights into process that maintain integrity function patients receiving immunotherapy. Moreover, dual of suppression damage described, revealing significance inflammatory cytokines, checkpoints, disturbances TME. Importantly, propose combination therapies integrating nutritional interventions or anti-inflammatory potential approaches for mitigating wasting. This study highlights need deeper investigations optimize improve its efficacy preserving health, thereby improving patient outcomes quality life.

Language: Английский

Combination of External Beam Radiation Therapy and Immune Checkpoint Inhibitors in Cancer Treatment: Mechanisms, Limitations, and Clinical Applications DOI
Anusha Muralidhar, Malick Bio Idrissou, Quaovi H. Sodji

et al.

Applied Radiation Oncology, Journal Year: 2025, Volume and Issue: 14(1), P. 17 - 25

Published: March 1, 2025

Abstract External beam radiation therapy (EBRT) has long been integral in cancer treatment, effectively targeting localized and metastatic tumors. Immunotherapy, especially immune checkpoint inhibitors (ICIs), leverages the system to eliminate cells but faces challenges such as treatment resistance. EBRT may provide an approach overcoming resistance ICI therapy, thus enhancing ICIs’ efficacy broadening their clinical scope. EBRT, by inducing immunogenic cell death, primes can potentiate ICIs. This combination strategy shown promise preclinical studies, highlighting potential of overcome limitations monotherapy vice versa. Clinical trials have demonstrated safety feasibility this combination, with evidence suggesting improved tumor control patient outcomes. Nevertheless, numerous remain. review explores mechanisms, challenges, evaluating ICIs, underscoring need for optimized approaches maximize efficacy, while minimizing toxicities.

Language: Английский

Citations

0
Acquired resistance to immunotherapy in solid tumors DOI

Perrine Verdys,

Astrid Z. Johansen, Anurag Gupta

et al.

Trends in Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors DOI Creative Commons

Besan H. Al-Saafeen,

Bassam R. Ali, Eyad Elkord

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 24, 2025

Over the past few years, immune checkpoint inhibitors resulted in magnificent and durable successes treating cancer; however, only a minority of patients respond favorably to treatment due broad-spectrum tumor-intrinsic tumor-extrinsic factors. With recent insights gained into mechanisms resistance, combination strategies overcome resistance enhance therapeutic potential are emerging showing promising results both pre-clinical clinical settings. This has been derived through multiple interconnected such as enhancing tumor immunogenicity, improving neoantigen processing presentation addition augmenting T cell infiltration cytotoxic potentials. In settings, several avenues treatments involving were associated with considerable improvement outcome terms patient’s survival growth control. This, turn, increased spectrum cancer benefiting from unprecedented effects leading their adoption first-line for certain cancers. Moreover, significance precision medicine immunotherapy unmet demand develop more personalized predictive biomarkers also highlighted this review.

Language: Английский

Citations

0
Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy DOI Creative Commons
Shuang Ma, Guangyu Zhao,

S.J. Sui

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Cancer immunotherapy, which leverages the immune system to target neoplastic cells, has undergone significant transformation in recent. However, immunotherapy may have negative effects on skeletal muscle function, causing wasting and functional decline cancer patients. In this study, we review mechanisms by influences muscle, focusing immune-related myositis, inflammation, metabolic alterations within tumor microenvironment (TME). The key methodologies, including biomechanical assessment techniques such as electrical impedance myography ultrasound imaging, are discussed provide valuable insights into process that maintain integrity function patients receiving immunotherapy. Moreover, dual of suppression damage described, revealing significance inflammatory cytokines, checkpoints, disturbances TME. Importantly, propose combination therapies integrating nutritional interventions or anti-inflammatory potential approaches for mitigating wasting. This study highlights need deeper investigations optimize improve its efficacy preserving health, thereby improving patient outcomes quality life.

Language: Английский

Citations

0